BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27884650)

  • 21. Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
    Tafur AJ; Caprini JA; Cote L; Trujillo-Santos J; Del Toro J; Garcia-Bragado F; Tolosa C; Barillari G; Visona A; Monreal M;
    Thromb Haemost; 2017 Jun; 117(6):1192-1198. PubMed ID: 28276571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous Thromboembolism.
    Brenner B; Bikdeli B; Tzoran I; Madridano O; López-Reyes R; Suriñach JM; Blanco-Molina Á; Tufano A; Núñez JJL; Trujillo-Santos J; Monreal M;
    Am J Med; 2018 Sep; 131(9):1095-1103. PubMed ID: 29807000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy.
    Tzoran I; Brenner B; Sakharov G; Trujillo-Santos J; Lorenzo A; Madridano O; López-Sáez JB; Monreal M;
    Eur J Intern Med; 2014 Nov; 25(9):821-5. PubMed ID: 25287697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry.
    Gussoni G; Frasson S; La Regina M; Di Micco P; Monreal M;
    Thromb Res; 2013 Jan; 131(1):24-30. PubMed ID: 23141849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.
    Hutten BA; Prins MH; Gent M; Ginsberg J; Tijssen JG; Büller HR
    J Clin Oncol; 2000 Sep; 18(17):3078-83. PubMed ID: 10963635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry.
    Yamashita Y; Morimoto T; Klok FA; Barco S; Nishimoto Y; Kato T; Ono K; Kimura T;
    J Thromb Thrombolysis; 2022 Oct; 54(3):524-534. PubMed ID: 35713842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uterine bleeding during anticoagulation in women with venous thromboembolism.
    Moustafa F; Fernández S; Fernández-Capitán C; Nieto JA; Pedrajas JM; Visoná A; Valero B; Marchena PJ; Braester A; Monreal M;
    Thromb Res; 2017 Mar; 151 Suppl 1():S1-S5. PubMed ID: 28262225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
    Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J
    Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer.
    van der Hulle T; den Exter PL; van den Hoven P; van der Hoeven JJ; van der Meer FJ; Eikenboom J; Huisman MV; Klok FA
    Chest; 2016 May; 149(5):1245-51. PubMed ID: 26836911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.
    Haas SK; Freund M; Heigener D; Heilmann L; Kemkes-Matthes B; von Tempelhoff GF; Melzer N; Kakkar AK;
    Clin Appl Thromb Hemost; 2012; 18(2):159-65. PubMed ID: 22275397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
    Davidson BL; Verheijen S; Lensing AW; Gebel M; Brighton TA; Lyons RM; Rehm J; Prins MH
    JAMA Intern Med; 2014 Jun; 174(6):947-53. PubMed ID: 24733305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose aspirin for preventing recurrent venous thromboembolism.
    Brighton TA; Eikelboom JW; Mann K; Mister R; Gallus A; Ockelford P; Gibbs H; Hague W; Xavier D; Diaz R; Kirby A; Simes J;
    N Engl J Med; 2012 Nov; 367(21):1979-87. PubMed ID: 23121403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II.
    Spirk D; Ugi J; Korte W; Husmann M; Hayoz D; Baldi T; Frauchiger B; Banyai M; Aujesky D; Baumgartner I; Kucher N
    Thromb Haemost; 2011 Jun; 105(6):962-7. PubMed ID: 21475778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry.
    Ruíz-Giménez N; Suárez C; González R; Nieto JA; Todolí JA; Samperiz AL; Monreal M;
    Thromb Haemost; 2008 Jul; 100(1):26-31. PubMed ID: 18612534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry.
    Nieto JA; Camara T; Gonzalez-Higueras E; Ruiz-Gimenez N; Guijarro R; Marchena PJ; Monreal M;
    Thromb Haemost; 2008 Nov; 100(5):789-96. PubMed ID: 18989522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study.
    Mantha S; Laube E; Miao Y; Sarasohn DM; Parameswaran R; Stefanik S; Brar G; Samedy P; Wills J; Harnicar S; Soff GA
    J Thromb Thrombolysis; 2017 Feb; 43(2):166-171. PubMed ID: 27696084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of arterial and venous thromboembolic events among patients with colorectal carcinoma: a real-world, population-based study.
    Abdel-Rahman O; Wu C; Easaw J
    Future Oncol; 2021 Oct; 17(30):3977-3986. PubMed ID: 34342490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of recurrent venous thromboembolism in cancer patients.
    Romualdi E; Ageno W
    Thromb Res; 2016 Apr; 140 Suppl 1():S128-31. PubMed ID: 27067966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.